Literature DB >> 7489810

Normal pregnancy in primary alveolar hypoventilation treated with nocturnal nasal intermittent positive pressure ventilation.

T Pieters1, J J Amy, D Burrini, G Aubert, D O Rodenstein, P Collard.   

Abstract

Nocturnal nasal intermittent positive pressure ventilation (NIPPV) is increasingly used to treat chronic respiratory failure in a wide variety of conditions (myopathies, Ondine's curse, kyphoscoliosis, etc.) and allows a normal everyday life. Some of these diseases affect women of childbearing age. We report on a young woman suffering from primary alveolar hypoventilation, who presented with limitation of daytime activities, severe oxygen desaturation during sleep, polycythaemia and pulmonary hypertension. These abnormalities completely reversed after a few months of NIPPV applied through a nasal mask. Whilst under ventilatory assistance during sleep, she had an uneventful pregnancy and delivery of a normal baby. We suggest that in selected patients requiring NIPPV, pregnancy can be contemplated with a reasonable level of safety both for the mother and the child, provided that adequate mechanical ventilatory assistance during sleep is maintained throughout pregnancy.

Entities:  

Mesh:

Year:  1995        PMID: 7489810     DOI: 10.1183/09031936.95.08081424

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  3 in total

1.  Noninvasive ventilation for the management of pulmonary hypertension associated with congenital heart disease in children.

Authors:  H J Bunn; P Roberts; A H Thomson
Journal:  Pediatr Cardiol       Date:  2004 Jul-Aug       Impact factor: 1.655

2.  Pregnancy assisted by nasal intermittent positive pressure ventilation in a patient with cystic fibrosis.

Authors:  J A Butler; L J Restrick; G M Esmond; C Mickelsons; D W Empey
Journal:  J R Soc Med       Date:  1997-04       Impact factor: 5.344

3.  Use of noninvasive positive pressure ventilation during pregnancy: case series.

Authors:  Mariam A Al-Ansari; Akmal A Hameed; Suhaila E Al-jawder; Hassan M Saeed
Journal:  Ann Thorac Med       Date:  2007-01       Impact factor: 2.219

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.